Last reviewed · How we verify

NCT06790849

ETASCAI Pilot Project

Completed NA Last updated 19 November 2025
What this trial tests

NA trial testing Active 1 ETAS® in Cognition in 45 participants. Completed in 22 October 2025.

Timeline
24 February 2025
Primary endpoint
22 October 2025
22 October 2025

Quick facts

Lead sponsorUniversity of Reading
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposebasic science
Enrollment45
Start date24 February 2025
Primary completion22 October 2025
Estimated completion22 October 2025
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Reading

Who can join

Adults 60 to 80, any sex, with Cognition or Affect (Mental Function). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot study aims to investigate the chronic effects of ETAS® on cognitive, affective and inflammatory outcomes in healthy adults aged 60-80 years with mild to moderate subjective cognitive complaints.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cognition

Currently open trials in the same condition.

Other University of Reading trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06790849.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing